Perspectives: ADHD Med Shortage Shows No Sign Of Easing; Why Are Pro-Life Groups Targeting PEPFAR?

USA Today: Adderall Shortage Is Still Happening. Don't Expect A Quick Remedy
A 27-year-old patient of mine has taken Adderall since early adolescence. A successful bonds trader who works long hours, he gives Adderall part of the credit for his success in business. (Dr. Marc Siegel, 9/5)

The New York Times: I’m A Pro-Life Priest. Anti-Abortion Groups Are Wrong To Oppose PEPFAR
The debate over PEPFAR kicked off in May when the Heritage Foundation, a conservative think tank, published a report that, without any substantiation, accused PEPFAR of “promoting” abortion. That same report callously referred to H.I.V. as a “lifestyle disease” and framed antiretroviral therapy as a partisan talking point. (Richard W. Bauer, 9/5)

The New York Times: 4 Arguments You Will Hear Against Medicare Drug Price Negotiations
President Biden recently announced the first 10 drugs that will be subject to price negotiations with Medicare. They include drugs to treat diabetes, heart disease, blood cancer, blood clots and rheumatoid arthritis — diseases that affect millions of Americans. (Larry Levitt, 9/6)

Bloomberg: Ozempic Cuts Alcohol Cravings. Liquor, Beer And Wine Companies Aren’t Ready
The alcohol industry has been thriving despite a streak of threats: the legalization of marijuana, a trade war with China that has hampered US exports, the rise of the sober-curious movement. Now a new risk, one few investors or companies are publicly acknowledging, could pressure sales: weight loss drugs. (Lisa Jarvis and Leticia Miranda, 9/1)

The New York Times: A Filmmaker’s Final Goodbye To Opiates 
For most of my adult life, I’ve struggled with an opiate addiction of some form. But I’m one of the lucky ones, because I’m still here. The dark descent into the nefarious underworld of heroin addiction is well documented, but the challenging and deeply personal world of recovery and hope is rarely seen. (Miranda Stern, 9/5)